Vortioxetine filed in the US and EU – Revenue from New Products doubled

Third quarter report 2012
Vortioxetine filed in the US and EU – Revenue from New Products doubled


H. Lundbeck A/S (Lundbeck) reports revenue of DKK 3,563 million for the third quarter of 2012, excluding Lexapro® in the US, an increase of 2% compared to the same period last year. EBITDA and EBIT were DKK 846 million and DKK 661 million respectively, corresponding to an EBITDA margin of 23.4% and an EBIT margin of 18.2%. Profits were affected by the increase in launch costs associated with Lundbeck's newer products, as well as the loss of revenue from Lexapro due to generic competition.
- Lundbeck's novel multimodal antidepressant, vortioxetine, filed in Europe, Canada and the US - a treatment that may benefit patients with depression who are seeking additional therapeutic options
- New Products* increased 100% and constituted 17% of revenue for the third quarter
- OnfiTM revenue in the US is on track to meet expectations and generated revenue of DKK 174 million for the first nine months of 2012
- Escitalopram in Japan now holds a market share of 6.1% and for the first nine months generated a royalty of DKK 133 million
- Third quarter revenue in the US, excluding Lexapro, increased 44%
- Treanda® launched in Canada, and Azilect® launched in Thailand, Hong Kong and Australia
- Lundbeck is on track to meet financial expectations for 2012

Click here to read the full report >> (PDF)

Suggested Articles

Trump has said the coronavirus outbreak doesn't pose a major threat to the U.S., but the White House is weighing naming a "czar," Politico…

After a major label expansion in December, Amarin's Vascepa is preparing a major boom in sales with its marketing team nearly scaled up.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.